by | Jan 14, 2025 | Lupus Foundation of America, News & Events
The Phase 1 GALLOP study evaluating investigational therapy, CB-010, for treatment of lupus nephritis (LN) has officially started. This open label, multicenter study will assess a single infusion of CB-010 in adults with LN, including those with extrarenal lupus (ERL,...
by | Jan 14, 2025 | Lupus Foundation of America, News & Events
The Phase 1 GALLOP study evaluating investigational therapy, CB-010, for treatment of lupus nephritis (LN) has officially started. This open label, multicenter study will assess a single infusion of CB-010 in adults with LN, including those with extrarenal lupus (ERL,...
by | Jan 13, 2025 | Lupus Foundation of America, News & Events
Lupus affects different people in different ways, and skin problems like rashes or sores re common. In a new study, people with systemic lupus erythematosus (SLE) were found to be at higher risk for developing multiple cutaneous lupus erythematosus disease (CLE, lupus...
by | Jan 10, 2025 | Lupus Foundation of America, News & Events
IGM Biosciences announced they are halting the development of two investigational drugs for autoimmune and inflammatory diseases, imvotamab (an IgM-based CD20 X CD3 bispecific antibody T cell engager) and IGM-2644 (an IgM-based CD38 X CD3 bispecific antibodyT cell...
by | Jan 10, 2025 | Lupus Foundation of America
January is Mental Wellness Month! We asked Heather Rose Artushin, a licensed clinical social worker, to share information and insights into understanding and protecting your mental health when you have lupus.This blog post is the first in a four-part series that we...
by | Jan 9, 2025 | Lupus Foundation of America, News & Events
In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess therapies for initial management of lupus nephritis (LN), focusing on their design with study populations and outcomes, examining the results and...
